CurifyLabs Secures, 12M to Scale 3D Printing Medicine in U.S.

Helsinki-based CurifyLabs has closed a, 12 million Series A funding round to accelerate its entry into the U.S. market. The capital injection targets the scaling of 3D printing infrastructure for personalized medicine compounding, signaling a shift toward localized pharmaceutical production. Co-led by Sandwater and HealthCap, with participation from Tesi, the round provides the necessary liquidity to bolster supply chain resilience and expand product innovation capabilities. This move highlights a growing institutional appetite for HealthTech solutions that decentralize traditional drug manufacturing. By utilizing 3D printing technology, CurifyLabs aims to streamline the creation of personalized dosages, a segment of the healthcare market that has historically faced high overhead and logistical friction. The decision to prioritize U.S. operations suggests that the company is positioning itself to capture market share within the world's largest pharmaceutical economy. Investors and industry analysts should monitor how this capital deployment influences the competitive landscape for automated compounding systems. As CurifyLabs scales its U.S. footprint, the focus will likely shift to regulatory navigation and the integration of its hardware into existing clinical workflows. The ability to demonstrate efficiency gains in medicine compounding could serve as a catalyst for broader adoption of additive manufacturing in the pharmaceutical supply chain. While the funding round marks a significant milestone for the firm, the long-term impact remains contingent on the speed of infrastructure deployment and the ability to meet stringent U.S. healthcare compliance standards. Market participants should watch for further partnerships between CurifyLabs and domestic healthcare providers, as these alliances will be critical to establishing a foothold in the competitive American landscape. The infusion of, 12 million provides the runway to test these operational models at scale, potentially setting a benchmark for how personalized medicine is delivered in a clinical setting. For those tracking the intersection of 3D printing and biotech, this development underscores a broader trend of capital flowing into technologies that promise to reduce waste and improve patient outcomes through precision manufacturing. The next few months will be pivotal as the company transitions from European market validation to the complexities of U.S. expansion.